The nicotinic acetylcholine receptor (nAChR) was first characterized in 1970 as a membrane receptor of a neurotransmitter and an ion channel. nAChRs have been demonstrated to be involved in smoking-induced cancer formation in multiple types of human cancer cells. In vitro and in vivo animal studies show that homo-pentameric nAChR inhibitors, such as methyllycaconitine and α-Bgtx, can attenuate nicotine-induced proliferative, angiogenic, and metastatic effects in lung, colon, and bladder cancer cells. Recent publications have demonstrated that α9-nAChR is important for breast cancer formation. Several α9-nAChR-specific antagonists (such as α-ImI, α-ImI, Vc1.1, RgIA, and It14a) produce an analgesic effect in many in vivo studies. Additionally, Vc1.1 has functioned in a variety of animal pain models and has currently entered phase II clinical trials. For cancer therapy, natural compounds such as garcinol and EGCG have been found to block nicotine-and estrogen-induced breast cancer cell proliferation through inhibition of the α9-nAChR signaling pathway.
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Background
 Biological functions of nAChRs
Based on the ligand-binding properties, nAChRs have been divided into two classes: (a) α-bungarotoxin (α-Bgtx)-binding nAChRs containing α7 or α9 subunits, which form homopentamers, and (b) α-Bgtx non-binding nAChRs, which contain α2-α6 and β2-β4 subunits, which form heteromeric receptors with high affinities for receptor agonists (such as acetylcholine and nicotine) (1, 2) . Each of these receptor subtypes has distinct electrophysiological and pharmacological properties. For example, The α4β2-containing nAChRs have the highest nicotine-binding affinity in mammalian cells (3) . Once α4β2 nAChRs are stimulated, dopamine is released in the brain reward pathway which results in smoking addiction. In another case, α7-and α9-nAChR receptors have unique properties pertaining to the regulation of signaling mechanisms found in sensory epithelia (α7-nAChR) and other non-neuronal (α9-nAChR) cell types. Homopentamers of α7-nAChR are the most well-investigated subtype and important channels for Ca 2+ -dependent mechanisms, including activating second messengers such as PKA, PKC, PI3K/Akt, and MAPK ( Figure 1 ) (4). These signaling pathways are closely correlated to the formation of several cancers. In particular, α7-nAChR is associated with lung (5), bladder (6) , and colon cancers (7) while α9-nAChR is associated with breast cancer (8-10) ( Figure 1 ). The functional diversity of the nAChR family offers abundant prospects for the design of novel therapies. Therefore, nAChRs have been investigated as drug targets for nervous system disorders (11).
Homopentamers of α7-nAChR are the most well-investigated subtype and are known to desensitize rapidly and have a Ca2 + :Na + permeability ratio (12) that is around four-fold higher than those of other nAChRs. The opening of nAChR channels impacts several Ca
2+
-dependent mechanisms, including activating second messengers (4) such as PKA, PKC, PI3K/Akt, and MAPK ( Figure 1 ). These signaling pathways are closely correlated to the formation of several cancers. In particular, α7-nAChR is associated with lung (5), bladder (6) , and colon cancers (7) and α9-nAChR is associated with breast cancer (8-10) ( Figure 1 ).
nAChRs are ligand-gated cation channels, and different subtypes are known to be differentially permeable to calcium ions (Ca2   + 4 homomeric receptors is significantly higher than that of heteromeric nAChRs. In particular, the α7-nAChR subtype has one of the highest calcium permeabilities; the activation of this receptor can raise cytoplasmic calcium levels and trigger a series of calcium-dependent intracellular processes (14) . Several studies have observed the presence of nAChRs in several non-neuronal, non-excitable cells, such as cells from the bronchial epithelium, endothelial cells, keratinocytes, immune cells, vascular smooth muscle cells and cells from other tissue types. The presence of these receptors in non-neuronal cells seems to suggest that they have distinct functions beyond neurotransmission (15) . Most recently, several studies have indicated that α7-nAChRs primarily mediate endothelial cell proliferation, invasion and angiogenesis (16) (17) (18) (19) .
Additionally, the presence of α7-nAChR inhibitors, such as methyllycaconitine (MLA) and α-Bgtx, can reverse the pro-angiogenic effects of nicotine (16, 17) . However, it is important to note that both α-Bgtx and MLA bind with high affinity to α9-nAChR.
Therefore, α9-nAChR may be partially involved in nicotine-induced pro-angiogenic effects (20) . In particular, α7-nAChRs have been found to activate the MAP kinase, PI3-kinase/Akt and NF-κB pathways, thereby mediating angiogenesis (16) (17) (18) .
 Molecular structure of nAChRs
Acetylcholine receptors (AChRs) are integral membrane proteins that respond to the binding of acetylcholine (ACh), which is synthesized, stored and finally released by cholinergic neurons (21) . Like many other ligand-activated neurotransmitter receptors, AChRs have been classified according to either their pharmacological properties or their relative affinities for various molecules. Therefore, they can be divided into two major subtypes: (a) the metabotropic muscarinic receptors (mAChRs)
found in vertebrate skeletal muscles, which mediate neuromuscular transmission at the neuromuscular junction and are particularly responsive to muscarine (22) , and (b) the ionotropic nicotinic receptors (nAChRs), which are particularly responsive to nicotine and found not only throughout the peripheral and central nervous systems but also in non-neuronal tissues (23) . Both share the properties of being activated by the endogenous neurotransmitter ACh and of being expressed by both neuronal and non-neuronal cells throughout the body (24) .
Previous papers have demonstrated that mAChRs are ligand-gated ion channel receptors primarily expressed in skeletal neuromuscular junctions, and they are composed of five subunits, including two α1 subunits, and one each of β1, δ, and γ (or ε, depending on the stage of development) (25) . Only two types of mAChRs are constructed from this complex subunit pool; one of the types is composed of α1, β1, δ, and γ subunits, and the other is composed of α1, β1, δ, and ε subunits, both at ratios of 2:1:1:1. In contrast, nAChRs were originally cloned from a neuronal-like cell line and brain cDNA libraries. They are expressed throughout the nervous system, and they functionally increase neuronal excitability and facilitate synaptic transmission (26). nAChRs can form either homopentamers or heteropentamers containing ten α-subunits (termed α1-α10), four non-α subunits (termed β1-β4), δ, γ, and ε. Notably, α8 has only been identified in avian libraries and has not been found in mammals (24) .
Expression of these nAChR subunits has been observed in many other cell types, including endothelial cells, glial cells, immune cells, and keratinocytes, as well as in gastrointestinal, lung, bladder, colon and breast tissues.
 nAChR-mediated signaling pathways
The first evidence that nAChRs regulate cancer growth was reported by Dr. H. M.
Schuller in 1989 (27) . In the following decades, studies have highlighted that nAChRs are key molecules acting as central regulators of a complex network that governs growth (5, 28) , angiogenesis (29) , metastasis (7) and apoptosis (30) during carcinogenesis in response to the tumor microenvironment. In addition, nAChRs stimulate intracellular signaling pathways in a cell type-specific manner. Figure 1 shows that nicotine-induced upregulation of growth factors (such as VEGF and βFGF) and their receptors is one of the major molecular mechanisms underlying the pro-angiogenic effects of nAChRs in several types of cancer cells (18, 29, 31) . Most intriguingly, VEGF and βFGF-induced human microvascular endothelial cell (HMVEC) migration requires nAChR activation. These studies suggest that nAChR and VEGF mediate distinct but interdependent pathways of angiogenesis (32) . forced expression of α9-nAChR (43) . Another important concern is that nAChRs can be induced in response to nicotine, NNN, and NNK exposure, which produces a detrimental feedback effect on receptor-ligand binding signaling. Such results indicate that receptor-mediated effects may play an important role in nicotine-induced carcinogenesis. Therefore, understanding nAChR-mediated mechanisms could offer useful and abundant prospects for the design of novel cancer therapies.
nAChR activation-mediated tumorigenesis
Cell type-specific oncogenesis occurs in response to different nAChR combinations. For example, high levels of α7-nAChR expression promote cancer cell proliferation and metastasis in lung, gastrointestinal and bladder tissues through ERK and Akt signal transduction (44) . Apart from α7-nAChRs, α4β2-nAChRs are evolutionarily the oldest heteromeric nAChR receptor and are predominately expressed in mammalian brain and lung tissues (44) . It has also been shown that the α4β2-nAChR subtype is crucial in mediating the effects of nicotine-induced dopamine release (45) . These effects promote cigarette smoking behavior through uncontrolled nicotine addiction, and they thus play a major role in disease progression (46) . The α9-nAChR homopentamer was originally identified in hair cells of the inner ear and is involved in synaptic transmission between efferent nerves and hair cells (47) . Recently, α9-nAChR has been found to have diverse functions, such as keratinocyte adhesion (48), immune responses (49), neuropathic pain (50) and even breast cancer formation (43) . The correlation between α9-nAChR mRNA expression level and disease outcome in breast tumor patients was evaluated in a recent study (43) . In this study, 186 (67.3%) of the 276 paired samples expressed α9-nAChR mRNA at higher levels (mean 7.84-fold) in breast cancer than in surrounding normal tissue. The highest α9-nAChR mRNA expression levels were detected in smoking-related, advanced-stage breast cancer tissues. These observations have led to the conclusion that nicotine binding to nAChRs may play a crucial role in human 
nAChR activation-mediated angiogenesis
Angiogenesis is a complex combinatorial process that is regulated by a balance between pro-and anti-angiogenic molecules (16) (17) (18) . An imbalance between pro-angiogenic and anti-angiogenic factors can result in pathological situations, either through deficit conditions (e.g., in inefficient healing, tissue ischemia) or through excess angiogenesis (e.g., atherosclerotic plaque development, diabetic retinopathy α8, and α9 nAChRs) and between α (α2-4 or α6) and β subunits (β2 or β4) in heteropetameric nAChRs (66) .
Over the last few years, the availability of high-resolution x-ray crystal structures of nAChRs in their ligand-free and ligand-bound forms has greatly increased our knowledge regarding nAChR structure and function (67) . However, the main difficulty in drug design is that at least 12 genes encode the neuronal nAChR subunits, and their gene products (9α and 3β subunits) assemble in various combinations, forming a broad diversity of pentamers with distinct pharmacological properties. Neurotoxins are commonly used to distinguish between nAchR subunit combinations (69) . The neurotoxins lophotoxin, neosurugatoxin, and Bgtx (70, 71) and the alkaloids DHβE (72) and erysodine (73) are competitive nAChR antagonists that display selectivity for β2-containing nAChRs, particularly the α4β2 subtype (74) . Among these nAChRs, the α7-nAChRs are known to be overexpressed in small cell lung carcinomas associated with smoking (75) . In this case, in vitro experiments have suggested that malignant growth can be halted using snake neurotoxins (α-neurotoxins) or snail conotoxins (α-conotoxins) (76, 77) , as they are competitive antagonists of α7-nAChR (78) . In vivo animal studies have further demonstrated that α7-nAChR inhibitors, such as MLA (79, 80) and α-Bgtx (81), can reverse the pro-angiogenic effects of nicotine and inhibit cancer cell growth (16, 17, 19, 82, 83) .
In a lung airway epithelial cell model (84) , normal human bronchial epithelial (NHBE) cells were forced to transform by nicotinic activation of Akt, altering their growth characteristics. Dysregulated NHBE growth after nicotine administration is consistent with in vivo observations that active smokers have increased proliferative indices when compared with those of former smokers. Protection from prolonged serum deprivation-induced apoptosis conferred by nicotine was found to be attenuatable by LY294002 or DHβE, and protection conferred by NNK was attenuatable by LY294002 or α-BTX. These studies show that in addition to promoting cellular survival and/or transformation, nicotine-induced nAChR activation or NNK-induced Akt signaling is required to diminish contact inhibition and reduce cellular dependence on exogenous growth factors and the extracellular matrix. These studies have revealed that specific antagonists can decrease the high levels of α7-nAChR expression in human cancer cells. In addition to α7-nAChR-specific antagonists, α9-nAChR-specific antagonists reduce ascending afferent excitatory pain pathway signaling and have analgesic effects in in vivo studies (50, 85) . As shown in Table 1 , several nicotinic antagonists have either launched or entered phase II clinical trials (86, 87) . Unfortunately, most of the antagonists have also caused a variety of side effects due to the lack of nAChR subtype specificity. Among these α9-nAChR-specific antagonists (50, 88-92), Vc1.1 has profound analgesic effects in a variety of animal pain models and has currently entered phase II clinical trials (93) . Vc1.1 should have off-label use potential against α9-nAChR-mediated cancer formation in the future. 
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